SCHEMBL26599005

SCHEMBL26599005

O=C(c1cccc(Cl)c1F)C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 2/20 0.44
CYP11B1 P15538 2/20 0.43
CYP11B2 P19099 1/20 0.43
TSHR P16473 1/20 0.42
CES1 P23141 3/20 0.42
CES2 O00748 2/20 0.42
PLA2G2D Q9UNK4 1/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
BCHE P06276 1/20 0.39
NOTUM Q6P988 1/20 0.39
MAPK1 P28482 1/20 0.39
POLB P06746 1/20 0.38
RORC P51449 1/20 0.38
RORB Q92753 1/20 0.38
P2RX1 P51575 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28846637 0.85 KAT6A (0.42) KAT6ACYP11B1CYP11B2TSHRCES1
SCHEMBL26599014 0.85 KAT6A (0.42) KAT6ACYP11B1CYP11B2TSHRCES1
SCHEMBL2369282 0.82 TSHR (0.59) TSHRCES1CES2PLA2G2DALDH1A1
SCHEMBL29477191 0.82 CES1 (0.58) CES1CES2ALDH1A1KDM4ELMNA
SCHEMBL1471234 0.82 CES1 (0.58) CES1CES2ALDH1A1KDM4ELMNA
SCHEMBL3793197 0.81 ALDH1A1 (0.47) TSHRCES1CES2PLA2G2DALDH1A1
SCHEMBL2194781 0.80 CES1 (0.63) KAT6ACES1CES2PLA2G2DALDH1A1
SCHEMBL3784559 0.79 CES1 (0.46) TSHRCES1CES2PLA2G2DALDH1A1
SCHEMBL9693738 0.78 KAT6A (0.47) KAT6ACYP11B1CYP11B2TSHRCES1
SCHEMBL413285 0.78 ALDH1A1 (0.54) KAT6ACYP11B1CYP11B2TSHRCES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250339402-A1 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FUNDAMENTAL PHARMA GMBH (DE) 2025-11-06 US disclosed
EP-4511355-A2 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FundaMental Pharma GmbH (DE) 2025-02-26 EP disclosed
WO-2024223617-A1 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FUNDAMENTAL PHARMA GMBH (DE) 2024-10-31 WO disclosed
WO-2023203254-A2 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FUNDAMENTAL PHARMA GMBH (DE) 2023-10-26 WO disclosed
WO-2023203254-A2 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FUNDAMENTAL PHARMA GMBH (DE) 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250339402-A1 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY TRPM4, GRM4, GRIN1 KAT6A 1584/4885CYP11B1 3790/4885CYP11B2 3974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.